MXPA04004809A - Conjugados de hormona de crecimiento humana modificada quimicamente. - Google Patents

Conjugados de hormona de crecimiento humana modificada quimicamente.

Info

Publication number
MXPA04004809A
MXPA04004809A MXPA04004809A MXPA04004809A MXPA04004809A MX PA04004809 A MXPA04004809 A MX PA04004809A MX PA04004809 A MXPA04004809 A MX PA04004809A MX PA04004809 A MXPA04004809 A MX PA04004809A MX PA04004809 A MXPA04004809 A MX PA04004809A
Authority
MX
Mexico
Prior art keywords
chemically
growth hormone
human growth
modified human
hgh
Prior art date
Application number
MXPA04004809A
Other languages
English (en)
Inventor
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA04004809A publication Critical patent/MXPA04004809A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion provee una hormona de crecimiento humana (hGH) con modificacion quimica, preparada mediante la union de un polimero soluble en agua con la proteina; la proteina con modificacion quimica, conforme a la presente invencion, puede tener una actividad de hGH mucho mas duradera que aquella de la hGH sin modificar, lo que permite una reduccion de dosis y un programa de oportunidades.
MXPA04004809A 2001-11-20 2002-11-20 Conjugados de hormona de crecimiento humana modificada quimicamente. MXPA04004809A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
MXPA04004809A true MXPA04004809A (es) 2004-08-11

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004809A MXPA04004809A (es) 2001-11-20 2002-11-20 Conjugados de hormona de crecimiento humana modificada quimicamente.

Country Status (25)

Country Link
EP (1) EP1453859A2 (es)
JP (2) JP2005525302A (es)
KR (2) KR20050044858A (es)
CN (1) CN1608079A (es)
AP (1) AP2004003050A0 (es)
AU (1) AU2002356990A1 (es)
BR (1) BR0214451A (es)
CA (1) CA2467731A1 (es)
CO (1) CO5580794A2 (es)
EA (2) EA008505B1 (es)
EC (1) ECSP045114A (es)
GE (1) GEP20063860B (es)
HR (1) HRP20040448A2 (es)
HU (1) HUP0500997A2 (es)
IL (1) IL162031A0 (es)
IS (1) IS7268A (es)
MA (1) MA27544A1 (es)
MX (1) MXPA04004809A (es)
NO (1) NO20042182L (es)
OA (1) OA13063A (es)
PL (1) PL374354A1 (es)
RS (1) RS53104A (es)
TN (1) TNSN04090A1 (es)
WO (1) WO2003044056A2 (es)
ZA (1) ZA200403907B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
CA2473526C (en) * 2002-01-18 2013-10-22 Biogen Idec Ma Inc. Polyalkylene polymer compounds and uses thereof
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
RS20050202A (en) 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005034988A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Long-acting molecules in sustained release formulations
CA2552043A1 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
EA200700380A1 (ru) * 2004-08-31 2007-10-26 Фармация Энд Апджон Компани Ллс Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
SG158148A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
MX2007007591A (es) * 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
WO2006111524A2 (en) 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
JP2009506096A (ja) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー ペグ化成長ホルモンの液状調製物
PL1954710T3 (pl) * 2005-11-08 2011-09-30 Ambrx Inc Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie
CA2882445A1 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
RU2009103198A (ru) 2006-07-07 2010-08-20 Ново Нордиск Хелс Кеа Аг (Ch) Новые белковые конъюгаты и способы их получения
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
EP2272875B1 (en) * 2008-04-03 2014-01-15 Biosteed Gene Expression Tech. CO., LTD. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
TWI421093B (zh) * 2008-07-31 2014-01-01 Pharmaessentia Corp 胜肽－聚合物綴合物
JP5977945B2 (ja) 2008-08-06 2016-08-24 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有するコンジュゲートタンパク質
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
CN102292349B (zh) 2009-01-22 2016-04-13 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
RU2012129674A (ru) 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
AU2011208625C1 (en) 2010-01-22 2022-08-18 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
CN107530403A (zh) 2014-11-06 2018-01-02 药华医药股份有限公司 用于长效型干扰素的剂量方案
HUE056849T2 (hu) 2014-11-21 2022-03-28 Ascendis Pharma Endocrinology Div A/S Hosszú hatástartalmú növekedési hormon adagolási formák
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Polymer conjugates and the il–7 group
KR102152437B1 (ko) * 2015-09-18 2020-09-07 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 장시간 작용형 아드레노메둘린 유도체
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE69128944T2 (de) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
KR20050044858A (ko) 2005-05-13
MA27544A1 (fr) 2005-10-03
EA200700431A1 (ru) 2008-02-28
IL162031A0 (en) 2005-11-20
NO20042182L (no) 2004-08-11
ECSP045114A (es) 2004-07-23
OA13063A (en) 2006-11-10
EA200400565A1 (ru) 2005-06-30
RS53104A (en) 2006-10-27
ZA200403907B (en) 2007-12-27
JP2005525302A (ja) 2005-08-25
AP2004003050A0 (en) 2004-06-30
GEP20063860B (en) 2006-06-26
HRP20040448A2 (en) 2006-02-28
IS7268A (is) 2004-05-17
EA008505B1 (ru) 2007-06-29
CN1608079A (zh) 2005-04-20
AU2002356990A1 (en) 2003-06-10
BR0214451A (pt) 2006-05-30
PL374354A1 (en) 2005-10-17
WO2003044056A3 (en) 2003-08-21
TNSN04090A1 (fr) 2006-06-01
CA2467731A1 (en) 2003-05-30
CO5580794A2 (es) 2005-11-30
KR20070072924A (ko) 2007-07-06
EP1453859A2 (en) 2004-09-08
HUP0500997A2 (en) 2007-11-28
JP2006321808A (ja) 2006-11-30
WO2003044056A2 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
MXPA04004809A (es) Conjugados de hormona de crecimiento humana modificada quimicamente.
MXPA05004993A (es) Conjugados de hormona del crecimiento humana modificados quimicamente.
DK1715887T3 (da) N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf
MX344559B (es) Compuestos de hormona de crecimiento humana recombinante unidos al peg.
WO2002057293A3 (en) Modified zinc finger binding proteins
BG108499A (en) A novel engineered superantigen for human therapy
AU2003303598A1 (en) Compositions, methods, and systems for inferring bovine breed
EP2279754A3 (en) Remodelling and glycoconjugation of human growth hormone (hGH)
PL370310A1 (en) Method of improving the growth performance of an animal
EP2107071A3 (en) Anti-EpCAM immunoglobulins
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
MXPA04000068A (es) Conjugados de progenipoyetina modificados quimicamente.
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker
WO2002099438A3 (en) Modulation of steroid hormone uptake
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
MXPA03007002A (es) Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
EP1437364A3 (en) Polypeptide binding to the androgen receptor and its potential use for treating breast cancer
YANG et al. Transmembrane TNF-α increases over soluble TNF-α in human lung cancer tissue
TW200635952A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal